Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, has entered into an exclusive agreement with Eversana to lead the U.S. commercialization of denileukin diftitox-cxdl, a novel immunotherapy for adults with relapsed or refractory stage 1 cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Under the partnership, Eversana will serve as Citius Oncology’s sole commercialization partner, providing integrated services across market access, distribution, and patient support. The therapy is expected to launch in the United States in the fourth quarter of 2025.
Denileukin diftitox-cxdl was approved by the Food and Drug Administration in August of 2024, and is the only systemic treatment for CTCL that targets the IL-2 receptor on malignant T-cells and T-regs, according to the press release announcing the agreement.
“With a complete top-tier distribution network in place, we believe we are well-positioned to deliver on our promise to the CTCL community and execute a successful launch,” said Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals.
